Showing results (391-400 of 552) with videos related to
Sort By:
Pageof 56
American Journal of Clinical Dermatology|June 18, 2024
Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of ExposureEric L Simpson, Jonathan I Silverberg, Audrey Nosbaum, et al.American Journal of Clinical Dermatology|February 22, 2023
Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical TrialsJonathan I Silverberg, Charles W Lynde, Katrina Abuabara, et al.Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|December 13, 2019
Validation of four single-item patient-reported assessments of sleep in adult atopic dermatitis patientsDonald Lei, Muhammad Yousaf, Sherief R Janmohamed, et al.Dermatology and Therapy|December 20, 2025
Short-Term Efficacy of Lebrikizumab Versus Dupilumab in Combination with Topical Corticosteroids in Adults with Moderate-to-Severe Atopic Dermatitis: Matching-Adjusted Indirect ComparisonRaj Chovatiya, April Armstrong, Leon Kircik, et al.JAMA Dermatology|February 1, 2023
Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical TrialsAmy S Paller, Jonathan I Silverberg, Michael J Cork, et al.Dermatology and Therapy|July 30, 2026
Achieving Minimal Disease Activity in Atopic Dermatitis Is Associated with Fewer Flares, Reduced Healthcare Resource Utilization, and Improved Disease Control: Analysis from the Real-World MEASURE-AD StudyJonathan I Silverberg, Vimal H Prajapati, Susanne Abraham, et al.BMJ Open|November 28, 2020
International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationaleKatrina Abuabara, Jonathan I Silverberg, Eric L Simpson, et al.Journal of the American Academy of Dermatology|August 27, 2025
Chronic skin conditions and life trajectories: development and validation of "Dermatology Long-Term Life Impact Measure (DLLIM)"Jonathan I Silverberg, Charbel Skayem, Ann'Laure Demessant Flavigny, et al.Lancet (London, England)|May 23, 2021
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trialKristian Reich, Henrique D Teixeira, Marjolein de Bruin-Weller, et al.Dermatology and Therapy|September 23, 2025
Do Allergic Comorbidities Alter the Efficacy and Safety of Abrocitinib or Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis?Eric L Simpson, Jonathan I Silverberg, Bob Geng, et al.Pageof 56